Alvotech (ALVO) Stock Price, Quote & News

Company Profile

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosim...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Website: www.alvotech.com

Address:

9, Rue de Bitbourg, Luxembourg, Luxembourg

Kosmokrat Mar. 14 at 1:12 PM

$ALVO In the last Business Update (December) $ALVO released additional detail about the CRL's received from the FDA. Short summary of the 3 issues in order of severity: 1.) Application of silicon oil in production machinery. In collaboration with the supplier of the machinery we will remove this going forward. 2.) Handling of product quality complaints. Due to increasing volume of shipments (from 200k products to over 2M) there was a reasonable uptake in product quality complaints in the US since our last inspection in 2024. We fully overhauled our process how we handle such complaints and are very confident that this addresses the FDA’s concerns. 3.) Environmental monitoring and microbial control. The FDA was only concerned about what could happen to our products, so far we never had any sterility issues or contamination in our products. For us this is a continuous improvement, we agree that there can always be improved safeguards.

0 · Reply

Kosmokrat Mar. 13 at 3:14 PM

$ALVO Product revenue was mainly based on AVT02 and AVT04 in 2025, by now (or very soon) we should have another 3 products in the market: AVT03, AVT05, and AVT06. Due to the delay of the US launches of AVT05 and AVT06 I expect 2026 to have moderate revenue growth, but still double digit revenue growth and a positive cash flow. There will be no need for any further capital injections, so dilution is under control now. Once the market realizes this, we will see the SP climbing up again.

1 · Reply

lmnopqrs Mar. 12 at 7:58 PM

$ALVO Im sorry...

0 · Reply

Kosmokrat Mar. 12 at 7:37 PM

$ALVO Just loaded up at these firesale prizes. Doubled my position today.

0 · Reply

Kosmokrat Mar. 12 at 7:36 PM

$ALVO Outlook for 2026 from their Dec Biz Update: → Following successful completion of the offering the amount raised is expected to fund the company through to cash flow positivity in Q4 2026 → Anticipate total revenues in the range of $650 700 million in 2026, reflecting continued double-digit sales growth → Adj.EBITDA expected to increase to $180-220 million, supported by higher volumes of commercialized products and launches of newly approved products in Europe, Japan and the UK → Alvotech assumes to receive U.S. approval by late 2026 for the 4 Biologics License Applications active with the FDA, with minimum impact on the topline, and remains optimistic to be the first or among the first with approved biosimilars to Simponi® and Simponi Aria® in the US → The lower end of the revenue range assumes the possibility of further delay of pending FDA approvals

0 · Reply

diggs24 Mar. 12 at 5:00 PM

$ALVO Added 750@$3.57

0 · Reply

diggs24 Mar. 12 at 3:05 PM

$ALVO Just going to keep adding as it falls I guess? I'm at 4,237@$3.93 ACC.

0 · Reply

diggs24 Mar. 12 at 3:02 PM

$ALVO 485@$3.65

0 · Reply

Kosmokrat Mar. 12 at 2:20 PM

$ALVO had some early success monetizing their first assets, 2026 will bring a shift of revenue towards newer assets. By the end of 2025 AVT04 nearly catches up with AVT02, while AVT06 remains non‑material until 2026. Product revenue accounts for ~58–63% of total FY 2025 revenue. For 2026 I expect the following split for the product revenue: AVT04: 38–45% AVT06: 25–32% AVT02: 18–25% AVT05: 3–6% Other: 5–10% $ALVO forecasted total revenue of $650 to 700 million in 2026 seems quite conservative, but I appreciate a more conservative look into the future, as the biosimilar market is extremely competitive. SP will most likely recover significantly as revenue and cash flow grows throughout 2026.

0 · Reply

Ray455 Mar. 11 at 6:01 PM

$ALVO bullish

0 · Reply

Royce Smaller-Companies Growth Fund FY 2025: What Worked

ACVA AVAV FROG FRPT HIMS NVO PAR

Feb 11, 2026, 11:00 AM EST - 4 weeks ago

Alvotech Announces Increase in Number of Own Shares

Feb 5, 2026, 3:00 AM EST - 5 weeks ago

Alvotech Announces Positive Top-Line Results from Pivotal Pharmacokinetic Study for Proposed Biosimilar to Entyvio®

Feb 2, 2026, 3:00 AM EST - 5 weeks ago

Alvotech enters supply and commercialization agreements for Canada and Australia & New Zealand covering multiple biosimilar candidates

Jan 21, 2026, 9:34 PM EST - 7 weeks ago

Alvotech: Why FDA Delays Don't Break The Bull Case

Jan 13, 2026, 3:22 PM EST - 2 months ago

Bragar Eagel & Squire, P.C. Continues Investigations into Alvotech and Beyond Meat on Behalf of Stockholders and Encourages Investors to Contact the Firm

BYND

Jan 7, 2026, 5:00 PM EST - 2 months ago

Correction: Transactions of Managers and Closely Associated Persons

Jan 6, 2026, 3:00 PM EST - 2 months ago

Transactions of Managers and Closely Associated Persons

Dec 31, 2025, 4:30 PM EST - 2 months ago

Alvotech Secures Term Loan Facility of USD 100 Million

Dec 29, 2025, 2:40 PM EST - 2 months ago

Changes in company's own shares

Dec 22, 2025, 3:26 PM EST - 2 months ago

Alvotech's Financial Calendar for 2026

Dec 22, 2025, 2:00 AM EST - 2 months ago

Alvotech announces European launch of first-in-market biosimilar to Simponi® (golimumab) globally by partner Advanz Pharma

Dec 17, 2025, 4:08 PM EST - 3 months ago

Alvotech (ALVO) Faces Investor Scrutiny Amid Manufacturing Deficiencies Severely Impacting Assurances of 2025 Revenues and Adjusted EBITDA, Stock Tumbles 33% -- Hagens Berman

Dec 17, 2025, 2:30 AM EST - 3 months ago

Alvotech Successfully Places USD 108 Million Senior Unsecured Convertible Bonds in a Significantly Oversubscribed Offering

Dec 16, 2025, 3:19 PM EST - 3 months ago

Alvotech (ALVO) Discusses Launch of $125 Million Commercial Bond Offering and Business Update Transcript

Nov 24, 2025, 5:30 AM EST - 3 months ago

Alvotech Announces Approval of AVT03, a Biosimilar to Prolia® and Xgeva® (denosumab) in the European Economic Area

Nov 20, 2025, 4:00 AM EST - 4 months ago

Alvotech and Advanz Pharma Receive Marketing Approval Across the European Economic Area for Gobivaz®, a First-in-Market Biosimilar to Simponi® (golimumab)

Nov 13, 2025, 10:51 AM EST - 4 months ago

Alvotech (ALVO) Q3 2025 Earnings Call Transcript

Nov 12, 2025, 4:40 PM EST - 4 months ago

Alvotech Reports Results for the First Nine Months of 2025 and Provides a Business Update

Nov 10, 2025, 5:28 PM EST - 4 months ago

Scott+Scott Attorneys at Law LLP Reminds Investors of Its Investigation into Alvotech (NASDAQ: ALVO)

Nov 6, 2025, 6:28 PM EST - 4 months ago

Scott+Scott Attorneys at Law LLP Alerts Investors of Its Investigation into Alvotech (NASDAQ: ALVO)

Nov 6, 2025, 9:07 AM EST - 4 months ago

Alvotech and Advanz Pharma Receive Marketing Authorisations for Gobivaz®, a Biosimilar to Simponi® (golimumab), from the MHRA

Nov 4, 2025, 4:01 PM EST - 4 months ago

Alvotech Announces Webcast on November 13, 2025 to Report Financial Results for the First Nine Months of 2025 and Provide a Business Update

Nov 3, 2025, 1:17 PM EST - 4 months ago

Alvotech Shares Plunge 33% After FDA Flags Issues

Nov 2, 2025, 5:12 PM EST - 4 months ago

Alvotech Provides Update on the Status of U.S. Biologics License Application for AVT05

Oct 22, 2025, 5:00 AM EDT - 5 months ago

Alvotech Announces Changes in Global Business Development and Commercial Operations Team

Oct 15, 2025, 4:18 AM EDT - 5 months ago

Alvotech: Promising Vertically Integrated Biosimilar Platform

Oct 6, 2025, 1:29 PM EDT - 5 months ago

My Top 5 Biotech Stocks Big Pharma Could Buy Next

ABBV AMGN ARKG AZN BIIB BMY GILD

Oct 6, 2025, 4:40 AM EDT - 5 months ago

European Marketing Application for AVT23, a Proposed Biosimilar to Xolair® (omalizumab), Accepted by the European Medicines Agency

Sep 22, 2025, 6:15 AM EDT - 6 months ago

European Medicines Agency Recommends Marketing Authorization of AVT03, Alvotech's Proposed Biosimilar to Prolia® and Xgeva®

Sep 22, 2025, 4:30 AM EDT - 6 months ago

European Medicines Agency Recommends Marketing Approval of Gobivaz®, Alvotech's Proposed Biosimilar to Simponi® (golimumab) with Advanz Pharma as Commercialization Partner

Sep 19, 2025, 7:45 AM EDT - 6 months ago

Alvotech Announces Marketing Approval in Japan of Three New Biosimilars

Sep 10, 2025, 1:28 PM EDT - 6 months ago

Alvotech (ALVO) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 4, 2025, 9:15 AM EDT - 6 months ago

Alvotech Meets Investors and Participates in a Fireside Chat at the Morgan Stanley 23rd Annual Global Healthcare Conference in New York

Aug 21, 2025, 4:30 AM EDT - 7 months ago

Advanz Pharma and Alvotech receive European approval for Mynzepli®, Biosimilar to Eylea®

Aug 20, 2025, 6:05 AM EDT - 7 months ago

Alvotech appoints Patrik Ling as VP of Investor Relations Scandinavia

Aug 14, 2025, 11:38 AM EDT - 7 months ago

Alvotech (ALVO) Q2 2025 Earnings Call Transcript

Aug 13, 2025, 4:15 PM EDT - 7 months ago

Alvotech Reports Results for the First Six Months of 2025 and Provides a Business Update

Aug 13, 2025, 4:15 PM EDT - 7 months ago

Alvotech Reports Results for the First Six Months of 2025 and Provides a Business Update

Aug 6, 2025, 8:00 AM EDT - 7 months ago

Alvotech Announces Webcast to Report Financial Results for the First Half of 2025 on August 14, 2025, at 8:00 am EDT

Jul 10, 2025, 4:40 AM EDT - 8 months ago

Alvotech Appoints Linda Jónsdóttir as Chief Financial Officer

Jul 9, 2025, 4:30 AM EDT - 8 months ago

Alvotech Expands its Capacity in Assembly and Packaging with the Acquisition of Ivers-Lee Group in Switzerland

Jul 9, 2025, 4:30 AM EDT - 8 months ago

Alvotech Expands its Capacity in Assembly and Packaging with the Acquisition of Ivers-Lee in Switzerland

Jul 3, 2025, 7:02 PM EDT - 9 months ago

Notification for the purposes of article 13 of the Luxembourg law of 11 January 2008 on transparency requirements for issuers

Kosmokrat Mar. 14 at 1:12 PM

0 · Reply

Kosmokrat Mar. 13 at 3:14 PM

1 · Reply

lmnopqrs Mar. 12 at 7:58 PM

$ALVO Im sorry...

0 · Reply

Kosmokrat Mar. 12 at 7:37 PM

$ALVO Just loaded up at these firesale prizes. Doubled my position today.

0 · Reply

Kosmokrat Mar. 12 at 7:36 PM

0 · Reply

diggs24 Mar. 12 at 5:00 PM

$ALVO Added 750@$3.57

0 · Reply

diggs24 Mar. 12 at 3:05 PM

$ALVO Just going to keep adding as it falls I guess? I'm at 4,237@$3.93 ACC.

0 · Reply

diggs24 Mar. 12 at 3:02 PM

$ALVO 485@$3.65

0 · Reply

Kosmokrat Mar. 12 at 2:20 PM

0 · Reply

Ray455 Mar. 11 at 6:01 PM

$ALVO bullish

0 · Reply

diggs24 Mar. 11 at 2:22 PM

$ALVO 330 more at $3.77

0 · Reply

JohnTill Mar. 10 at 5:36 PM

$ALVO This one is just itching to fill that gap and tag the 200MA, which would be basically a double from this price. I just keep adding below 4 and bids all the way down. Hard to believe that market is overlooking this one and I am getting up there is size.

1 · Reply

diggs24 Mar. 9 at 2:19 PM

$ALVO Added 330 more at $3.82

0 · Reply

diggs24 Mar. 5 at 6:58 PM

$ALVO Agreed. Sitting on a little over 3000 shares now.

1 · Reply

JohnTill Mar. 5 at 3:06 PM

$ALVO FDA approval fills the gap to $8 immediately but there are so many other item that could take this higher. In a few years they will be printing money and people will look back and wonder how they missed buying at 4 since the story was so well laid out. With my decent bids all the way down to 3.67 taken out this week at least I got the avg. down to 4.03 but was sweating on that drop. Just a few more pennies to breakeven and now only of my larger positions and cannot resist a good deal. Good luck to those long.

0 · Reply

diggs24 Mar. 4 at 5:45 PM

$ALVO Damn....was really hoping it would open at that $3.5X premarket price.

0 · Reply

Kosmokrat Mar. 4 at 4:50 PM

$ALVO The chart looks really bearish, but fundamentally I see this huge potential. But it might be a rocky ride until we see the long overdue reversal.

0 · Reply

diggs24 Mar. 3 at 5:50 PM

$ALVO Added 480@$3.77. Averaged down to $4.00.

0 · Reply

diggs24 Mar. 2 at 11:26 PM

$ALVO Added another 1k@$3.84. Up to 2600 shares at ACC $4.04

0 · Reply

JohnTill Mar. 2 at 3:07 PM

$ALVO Ouch - added 25% to the position at 3.82 avg. so far this morning. Low balls in place and on the fence if I want them hit or not. Getting painful.

0 · Reply

PARA_85 Mar. 2 at 2:54 PM

$ALVO in

0 · Reply

JohnTill Feb. 27 at 8:06 PM

$ALVO Any analyst model and report coming up should also be incorporating AVT16/80 for Entyvio, which faces a 2028 patent expiry and $6 billion in global revenue. The same applies to AVT33 for Keytruda, with its 2028 patent expiry and roughly $30 billion worldwide, and AVT19 for Dupixent, which goes off patent in 2030 and generates about $18 billion globally. On top of that, AVT23, AVT41, AVT10, AVT28 and a few others that are all targeting markets in the $2 billion to $4 billion range and launches in the next few years. This does not even count what they are cooking up and not announced yet. One of these days we will wake up to this up 60% with no changes and just the market waking up to the facts.

0 · Reply

Market Cap	1.05B
Revenue (ttm)	489.68M
Net Income (ttm)	-231.86M
EPS (ttm)	N/A
PE Ratio	15.09
Forward PE	7.22
Profit Margin	-47.35%
Debt to Equity Ratio	-6.36

Volume	550,200
Avg Vol	503,452
Day's Range	N/A - N/A
Shares Out	301.48M
Stochastic %K	3%
Beta	0.16
Analysts	Sell
Price Target	$8.60